Compare Cassava Sciences Inc (FLNA) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Banco Santander SA — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Banco Santander SA trades at $14.82 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 4432× Cassava Sciences Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SAN | |
|---|---|---|
Market Cap | $47.75M | $211.63B |
Sector | Health | Financials |
52-Week High | $4.64 | $14.71 |
52-Week Low | $0.87 | $9.37 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Santander (SAN) trades at $14.80, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a 26.25% net income margin and a P/E of 14.4. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, expected to close in August 2026, which may enhance its US market presence.
The outlook is positive, supported by analyst consensus (64% buy ratings) and record profitability. Key risks include volatile cash flows, with negative net cash flow in 2024, and integration challenges from the Webster deal. Revenue growth remains a catalyst, but investors should monitor execution risks and macroeconomic pressures on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
